Every now and then, an industry comes along that rewires the whole economy. Biomanufacturing in China is shaping up to be that story.
By 2025, China’s biomanufacturing sector had already hit 1.1 trillion yuan (roughly $152 billion) in total output. Chinese manufacturers now produce over 70% of the world’s fermented bioproducts. Food ingredients and additives alone account for more than 400 billion yuan annually. Biopharma matches that number. Together, they form the two pillars of an industry that is quietly reshaping how China makes things.
This is not a niche. This is a structural shift.
From Policy Signal to National Strategy
Watch how a government signals seriousness and the language shift tells you everything. In 2022, biomanufacturing appeared in China’s 14th Five-Year Plan as a “strategic emerging industry.” By 2024, it made the government work report as a “new growth engine.” The 15th Five-Year Plan recommendations went further, giving it a dual designation: both a “key core technology” requiring breakthroughs and a “future industry” to be cultivated.
That dual positioning means biomanufacturing is being treated as both a hard tech problem and an industrial pillar. It is not just about lab discoveries. It is about building supply chains, replacing petrochemical infrastructure, and planting a flag in the next wave of global manufacturing competition.
Local governments are following through. Guangdong set a 2027 target of 500 billion yuan for its biomanufacturing sector. Shenzhen launched an industry guidance fund worth over 10 billion yuan, with individual major projects eligible for up to 100 million yuan in support. Beijing’s Yizhuang Development Zone aims to add two listed biomanufacturing companies by 2028 and cultivate 20 leading firms in the space.
The Money Is Moving
One reliable sign that an industry has crossed from curiosity to conviction: capital flows.
Between 2024 and 2025, China’s biomanufacturing sector attracted approximately 28 billion yuan in investment and financing. More than half of that went to healthcare applications, the highest-value segment. Seventeen individual companies raised over 100 million yuan each. Globally, synthetic biology investment has been compounding at roughly 30% annually since 2015.
The deal flow tells a story about where the industry is heading. One company raised over 500 million yuan for its green production of peptides, proteins, and nucleic acids. Another secured 200 million yuan for furan-based platform chemicals. A third, focused on human milk oligosaccharides, pulled in nearly 200 million yuan. None of these are abstract research projects. They are bets on scalable manufacturing assets.
And the state is not sitting on the sidelines. State-owned capital and strategic investment funds are placing large, deliberate bets across the board.
Three Technology Breakthroughs Worth Watching
Behind the macro numbers, specific scientific advances are opening new terrain.
1. C1 Biomanufacturing with Methanol Bacillus
Researchers at the Tianjin Institute of Industrial Biotechnology developed a methanol bacillus platform that uses methanol as the sole carbon source for biosynthesis. Methanol is cheap, energy-dense, and producible from CO2. They engineered a DNA transformation method 1,000 times more efficient than previous techniques and a CRISPR-Cas9 system with over 98% targeting lethality. The result is a plasmid-free, stable chassis that produces L-arginine from methanol alone. This is a serious step toward non-grain feedstock pathways.
2. Programmable Chromosome Editing (PCE)
A team led by Gao Caixia at the Institute of Genetics and Developmental Biology developed a technology called PCE (programmable chromosome editing) that achieves precise manipulation of DNA from kilobase to megabase scale. Published in Cell, the method enables targeted integration of 18.8 kb DNA fragments, directional replacement of 5 kb sequences, and even whole chromosome translocations. They used it to create herbicide-resistant rice germplasm with a 315 kb inversion. This is gene editing at a scale that was previously out of reach.
3. Multi-Enzyme Cascade Catalysis
East China University of Science and Technology built a multi-enzyme cascade system that now produces over 20 industrial and pharmaceutical products through biosynthesis. One standout application: squalene production through engineered yeast, where a single 20-ton fermentation tank replaces what would require 3,000 sharks. Over the past three years, the technology has contributed to more than 150 billion yuan in economic value and has been deployed across nearly 300 companies.
The Regional Puzzle: Four Distinct Plays
China’s biomanufacturing landscape is not monolithic. Different regions have carved out different specialties, and that diversity is a strategic asset.
Beijing and Tianjin function as the innovation engine room. They host dense concentrations of research institutes and national labs. Beijing’s Changping district became the first national-level SME cluster dedicated to synthetic biomanufacturing. The Jing-Jin-Ji (Beijing-Tianjin-Hebei) region signed a partnership agreement in 2025 to formalize a “Beijing R&D, Tianjin translation, Hebei support” model.
Shandong, Heilongjiang, and Henan are the workhorses. These agricultural provinces have abundant biomass resources and existing fermentation capacity. The “Sui-Ha-Da-Qi” cluster in Heilongjiang alone has a production value exceeding 60 billion yuan, with two companies reaching the 10-billion-yuan revenue mark.
Chongqing and Guangdong lead in biopharma innovation. Chongqing’s International Bio City has surpassed 110 billion yuan in output, with 56 innovative drugs in development. Guangdong targets 500 billion yuan in biomanufacturing output by 2027.
Shenzhen is the synthetic biology hub. The city now hosts over 370 synthetic biology companies. For every 100 new biomanufacturing firms founded nationwide, 40 land in Shenzhen. The Guangming District alone has over 130 companies with a combined valuation approaching 40 billion yuan.
The Companies Driving the Numbers
Four publicly listed companies anchor the industry’s competitive landscape.
Cathay Biotech (ticker: 688065) reported 3.295 billion yuan in 2025 revenue, up 11.4% year-on-year. It dominates the global market for bio-based long-chain dibasic acids, with annual sales exceeding 100,000 metric tons and gross margins of 42.88%. Its bio-based piperidine product captured a commanding share of the domestic market in its first year of sales.
Huaheng Biotech (ticker: 688639) reached 2.862 billion yuan in revenue, up 31.4%. It is the world’s top producer of L-alanine using anaerobic fermentation, with costs 50% lower than traditional enzymatic methods.
Bloomage Biotech (ticker: 688363) generated 4.199 billion yuan in revenue. It holds over 40% of the global hyaluronic acid raw material market. Unlike the others, Bloomage is building a consumer brand presence in skincare and medical aesthetics, an integrated model from raw material to end consumer.
Meihua Group (ticker: 600873), the bulk fermentation giant, posted 24.209 billion yuan in revenue and 3.281 billion yuan in net profit. Its scale and cost control give it formidable pricing power in animal nutrition amino acids and food ingredients.
Four Benchmark Cases
Microyx — PHA at Scale
Working with extremophile bacteria sourced from a salt lake in Xinjiang, a Tsinghua University spin-off built what is now China’s first 10,000-ton PHA production line. The core innovation: using halophilic (salt-loving) bacteria that grow in seawater and resist contamination, eliminating the need for sterile conditions. Production costs dropped over 40%. The company now produces 74 types of PHA, the widest product range globally, and holds food-contact certifications from China, the EU, and the United States.
East China University of Science and Technology — Squalene Without Sharks
Their multi-enzyme cascade system enables yeast to produce high-purity squalene at scale. A single 20-ton fermentation run replaces the yield from 3,000 sharks. The product now carries FDA and CDE certification and is used in vaccine adjuvants, cosmetics, and nutraceuticals.
Yikeli Biotech — The Enzyme Platform
Rather than focusing on a single product, Yikeli built a platform containing over 60,000 enzymes covering 20 classes of industrial reactions. The platform can analyze millions of enzyme sequences daily and run over 10,000 high-throughput validations. This has enabled nearly 20 products to reach commercial production, including rare sweeteners and human milk oligosaccharides. In 2025, it received 450 million yuan in strategic investment.
Nanjing Agricultural University — Cultured Meat at 2000-Liter Scale
In December 2025, Nanjing Agricultural University completed the world’s first 2,000-liter bioreactor trial production of cultured pork. This moves cell-cultured meat from lab-scale to pilot manufacturing, with annual capacity of 10 to 50 tons. It places China alongside Singapore, the US, Israel, Australia, and the UK in the race to commercialize cultured meat.
The Bottlenecks Nobody Is Ignoring
No honest assessment skips the problems.
The scale-up “valley of death” remains the hardest nut to crack. Research shows that only 30% of biomanufacturing innovations that skip pilot-scale testing succeed commercially, versus 80% for those that go through pilot validation. The government has responded by identifying 43 pilot-scale platforms in 2025, with a target of 20 national-level platforms by 2027.
High-end bioreactors still rely on imports. Western companies dominate the market for sophisticated fermenters and critical sensors. China’s Ministry of Industry and Information Technology launched a “leaderboard” program in 2025 to drive domestic substitution.
Feedstock dependence on grains creates tension with food security. The industry is shifting toward non-grain alternatives (straw, CO2, industrial waste gases) but the transition is early. The methanol bacillus platform and synthetic gas fermentation represent promising paths forward.
Where This Is Going
The projections are ambitious but grounded in observable trends. By 2030, China’s biomanufacturing sector is expected to reach 1.8 trillion yuan, accounting for nearly 25% of the global market. By 2050, global biomanufacturing could generate $30 trillion in economic value, roughly one-third of all manufacturing output.
The OECD estimates that less than 5% of current chemical products have been replaced by bio-based alternatives. That figure could reach 20% by 2030, representing an $800 billion market opportunity. McKinsey projects that 60% of all physical products could eventually be produced through biological routes.
China’s position in this transition is unusual. Unlike previous industrial revolutions where it played catch-up, China in biomanufacturing started roughly at the same time as advanced economies. It has scale advantages that no other country can match: 70% of global fermentation capacity, a complete industrial supply chain, and a government that has explicitly designated biomanufacturing as a national priority.
The next decade will test whether these advantages translate into global leadership. The ingredients are there. The execution is underway.